Last updated: February 15, 2026
What Is NDC 00536-1426?
NDC 00536-1426 is a specific formulation of a prescription drug approved by the FDA. Based on the National Drug Code (NDC), the drug is identified within the healthcare system's inventory. According to publicly available data, this code corresponds to Ritalin LA (methylphenidate extended-release capsules).
Market Overview
Ritalin LA (methylphenidate extended-release) is primarily used for treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. It competes within the stimulant medication market, sharing shelf space with drugs like Adderall XR, Vyvanse, and Concerta.
Market Size:
The global ADHD medication market is valued at approximately USD 12 billion in 2022, with the US accounting for about 70% of sales.
Market Drivers:
- Rising ADHD diagnosis rates (roughly 9.4% among children in the US, CDC 2016-2018)
- Increased awareness and acceptance of medication treatment
- Expanding adult ADHD treatment needs
Key Competitors:
- Adderall XR (amphetamines)
- Vyvanse (lisdexamfetamine)
- Concerta (methylphenidate extended-release)
Regulatory Influences:
- Continued DEA scheduling of stimulant medications may impact supply and pricing
- Patent expirations and generic entry affect market dynamics
Current Market Share and Sales Data
| Product |
Estimated US Market Share (2022) |
Estimated US Sales (USD millions) |
Pricing Trends |
| Ritalin LA |
15-20% |
USD 360-480 |
Historically priced between USD 200-300 per month per prescription; generic availability has driven prices downward |
| Adderall XR |
30-35% |
USD 720-1,050 |
Similar pricing; generic versions attend price competition |
| Vyvanse |
10-15% |
USD 240-360 |
Premium pricing, USD 300+ per month |
Pricing Dynamics
The list price for Ritalin LA is approximately USD 250-300 per month in branded form, with significant discounts achieved through pharmacy benefit managers (PBMs) and insurance plans. Generic methylphenidate extended-release formulations are available, reducing cost aligned with generic market trends.
Price Trends (2018-2022):
- List prices stabilized after years of decline amid generic competition.
- Average reimbursement rates from insurers have decreased by 10-15%, pressuring net prices.
Generics Impact:
- Generic formulations have captured 60-70% of the market share.
- Price per prescription of generics ranges USD 30-70 per month, offering a substantial price reduction.
Projections for 2023-2027
| Year |
Estimated US Market Size (USD) |
Expected Market Share |
Price Range (USD/month) |
Key Assumptions |
| 2023 |
USD 1.5 billion |
15-20% (stability) |
USD 250-300 (brand) |
Continued generic competition, volume growth |
| 2024 |
USD 1.6 billion |
15-20% |
USD 250-300 |
Potential patent or formulation updates |
| 2025 |
USD 1.7 billion |
14-18% |
USD 200-250 (generic) |
Patent expirations, increased generics |
| 2026 |
USD 1.8 billion |
13-17% |
USD 200-250 |
Market saturation, new formulations |
| 2027 |
USD 1.9 billion |
12-15% |
USD 200-250 |
Price stabilization, competition |
Note: Price stabilization around USD 200-250/month is projected for generics, with branded Ritalin LA maintaining a premium but declining share due to generics.
Regulatory & Patent Considerations
- The original patent for Ritalin LA expired in the US around 2018, with generics entering the market.
- Extended-release formulations often face patent challenges or are protected by formulation patents that may last until 2025, influencing pricing and market exclusivity.
- Any approval of new formulations or biosimilar entry could further pressure prices, especially after patent expiry.
Impact of Healthcare Policy
- Policy shifts toward biosimilars and generics to control healthcare costs will likely continue.
- PBM formulary decisions favor lower-cost generics, reducing revenue potential for branded Ritalin LA.
- Price negotiations with payers will be pivotal for maintaining profit margins.
Key Takeaways
- NDC 00536-1426 (Ritalin LA) operates within a mature, highly competitive ADHD treatment market in the US.
- Market share remains stable due to brand recognition, but generics dominate volume and lower prices.
- Branded prices range USD 250-300 per month; generics are priced significantly lower.
- Market growth will be driven by volume, with prices likely declining further, especially for generic formulations.
- Patent expirations by 2025 could accelerate price erosion and increase generic market penetration.
FAQs
Q1: How does the patent status of Ritalin LA affect its market?
Patents protecting Ritalin LA expired around 2018, allowing generic versions to enter, which has significantly lowered prices and market share for the branded version.
Q2: What potential factors could increase the price of NDC 00536-1426?
Limited manufacturing disruptions or formulation improvements could enable premium pricing, as well as regulatory exclusivities if claimed for new formulations.
Q3: How significant is the generic market for methylphenidate extended-release formulations?
Generics hold approximately 60-70% of the market share, heavily influencing overall market pricing and revenue.
Q4: What is the typical reimbursement rate for Ritalin LA?
Average reimbursement rates range from USD 250-300 per month for branded Ritalin LA, with lower rates for generics.
Q5: What future market trends could impact pricing?
Introduction of biosimilars, new formulations with improved efficacy, and healthcare policy changes promoting lower-cost generics could reduce prices further.
Sources:
- CDC. Data on ADHD prevalence.
- IQVIA. US pharmaceutical market data, 2022.
- FDA. Drug approval and patent information for methylphenidate formulations.
- Medicare & Medicaid services. Reimbursement and formulary data.
- Industry reports on ADHD market trends and projections.
